Luis
Montuenga Badía
Catedrático de Universidad
Jackeline
Agorreta Arrazubi
Publicaciones en las que colabora con Jackeline Agorreta Arrazubi (43)
2022
-
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity
The Journal of experimental medicine, Vol. 219, Núm. 12
-
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
DMM Disease Models and Mechanisms, Vol. 15, Núm. 1
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2020
-
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas
Cancer Immunology, Immunotherapy, Vol. 69, Núm. 10, pp. 2089-2100
2019
-
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Thorax, Vol. 74, Núm. 4, pp. 371-379
-
The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042
Journal of Clinical Medicine, Vol. 8, Núm. 8
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2018
-
A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients
Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432
-
Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects
American Journal of Respiratory and Critical Care Medicine, Vol. 197, Núm. 9, pp. 1164-1176
-
Complement C4d-specific antibodies for the diagnosis of lung cancer
Oncotarget, Vol. 9, Núm. 5, pp. 6346-6355
-
The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer
Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574
-
The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma
British Journal of Cancer, Vol. 118, Núm. 12, pp. 1596-1608
2017
-
A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis
Cancer Discovery, Vol. 7, Núm. 7, pp. 694-703
-
Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer
Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435
2016
-
Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536
2015
-
Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations
BMC Genomics, Vol. 16, Núm. 1
-
Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients
PLoS ONE, Vol. 10, Núm. 4
-
Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes
Journal of Thoracic and Cardiovascular Surgery, Vol. 150, Núm. 4, pp. 986-992.e11
2014
-
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
EMBO Molecular Medicine, Vol. 6, Núm. 4, pp. 539-550
-
RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner
Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206